A lung cancer trial bolsters a long-held idea that treatment timing matters, showing a simple shift could help immunotherapy ...

Brain metastases are far from a niche concern; with 100,000 to 200,000 cases diagnosed annually in the US, the scale of the ...

Immune Checkpoint Blockade (ICB) has revolutionized the treatment of cancers like melanoma, but up to 60% of patients don't ...

In conversation with THE WEEK, Dr Sewanti Limaye, Director of Medical & Precision Oncology at Sir H.N. Reliance Foundation Hospital, emphasised that personalised oncology is the future of cancer ...

The FDA approved pembrolizumab (Keytruda) plus paclitaxel for recurrent ovarian cancers that express PD-L1, the agency ...

Neoadjuvant immunotherapy could considerably improve long-term outcomes and quality of life for patients with desmoplastic melanoma, according to prospective study results.Nearly three-quarters of ...

Genetically modified immune cells can offer precious additional time to patients with advanced multiple myeloma. However, ...

A curious phenomenon seen by oncologists, that morning patients do better than those receiving afternoon infusions, gains ...

Long-term clinical trials show patients with stage four kidney cancer are living a decade or more beyond previous expectations.

Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a ...

Investigators analyzed economic evaluations of adjuvant immunotherapy to assess cost-effectiveness outcomes, quality-adjusted life-year (QALY)/life-year (LY) gains, and methodologic approaches.

By analyzing tissue from patients with Parkinson's disease, and animal and cellular models of the disease, a research team ...